We are accelerating the development of and access to new and innovative treatments for amyloidosis.

The Amyloidosis Research Consortium (ARC) is a global organization founded in 2015. Our mission is dedicated to changing the way research is being done and focuses on what will have the greatest impact on improving the lives of patients. We forge collaborations across industry, academia and regulatory to more rapidly advance the discovery of new treatments.